By Dan Levine and Marisa Taylor (Reuters) – U.S. drug inspectors recently recorded several new quality- control problems at an Eli Lilly and Co plant that is already the subject of a federal investigation over manufacturing lapses, according to a government report reviewed by Reuters. The U.S. Food and Drug Administration findings come nearly three years after the agency’s inspectors began documenting quality-control issues at the same Lilly plant in Branchburg, New Jersey. Last year, the U.S. Department of Justice launched a criminal investigation following a Reuters story that detailed alleg…